B-cell depletion continued for median 4 months (range, 2-9), and disease flare occurred at a median 6.6 months (range, 1.5-23) and was preceded by B-cell recovery in all but two patients. Rituximab was beneficial in refractory SLE including severe neurological and cardiorespiratory disease ...
. The same group treated PLN patients seen with severe proteinuric flare with oral CYC (1 to 2 mg/kg/day for 3 months) or RTX, followed by maintenance with MMF or AZA.88At 3 months, resolution of proteinuria (<0.5 g/24 hr) occurred in 20% of RTX-treated versus 7% of CYC-...
Our patient came with sepsis and a flare of SLE with involvement of three major organs, which was a puzzling scenario due to the lack of formal guidelines for co-management of sepsis and involvement of three major organs. In our opinion, since there is no evidence to support one over the...
Since RTX-associated cryoglobulinemia vasculitis flare has been linked to high mortality rate and resistance to corticosteroids and/or plasma exchange, cli- nicians should consider the following risk factors for this dangerous condition: renal vasculitis, B cell lymphoma, higher level of cryoglobulin, ...
4,5 In SLE, abnormalities of B-cell interactions with antigen-presenting cells and B-cell hyperactivity may drive the autoimmune process.6,7 THE EVIDENCE FOR RITUXIMAB RTX is an IgG1 κ mouse/human chimeric monoclonal antibody directed against the B-cell surface receptor CD20. It was licensed ...
Exploratory reanalysis of data from the EXPLORER trial was conducted, considering alternative definitions for flare. No difference was found between rituximab and placebo in preventing or delaying moderate to severe flares. However, when severe (BILAG A) flares alone were examined, rit...
Introduction Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease of unknown etiology. The evolution of the disease is unpredictable. Most patients follow a chronic course and have flare-ups or exacerbations, with a number of hospital admissions. Hypothesis and objectives The use of ...
Her SLE activity was well managed after PE and RTX without flare. PE treatment plan bridging to IS and RTX may effectively work in refractory SLE patients with infections.doi:10.1093/mrcr/rxad069Kagitani MakiFujiki YouheiSuzuka TakayasuOoe Katsumasa...
Therapy of systemic lupus erythematosus (SLE) is currently a challenging issue due to its multiple organ involvement, progressive evolution and intermittent flare deterioration. Conventional immunosuppressive regimens sometimes fail to treat severe manifestations. We report a case of a 19-year-old girl ...
Background and aimsB-cell-targeted therapies have been promising new treatments for SLE. Herein, we aimed to analyse the effects of Rituximab in lupus patients with involvement of different domains.MethodsThis is an analysis of 79lupus patients treated with rituximab at the rheumatology outpatient ...